Abstract
Glioma patients commonly suffer from epileptic seizures. However, the mechanisms of glioma-associated epilepsy are far to be completely understood. Using glioma-neurons co-cultures, we found that tumor cells are able to deeply influence neuronal chloride homeostasis, by depolarizing the reversal potential of γ-aminobutyric acid (GABA)-evoked currents (EGABA). EGABA depolarizing shift is due to zinc-dependent reduction of neuronal KCC2 activity and requires glutamate release from glioma cells. Consistently, intracellular zinc loading rapidly depolarizes EGABA in mouse hippocampal neurons, through the Src/Trk pathway and this effect is promptly reverted upon zinc chelation. This study provides a possible molecular mechanism linking glioma invasion to excitation/inhibition imbalance and epileptic seizures, through the zinc–mediated disruption of neuronal chloride homeostasis.
Similar content being viewed by others
Main
Glioma-associated epilepsy is an established but poorly understood phenomenon. Over 80% of glioma patients suffer from seizures,1 often representing the first symptomatic presentation of a tumor and possibly preceding it.2 It has been extensively reported that glioma cells release glutamate in the extracellular space, through the glutamate-cystine transporter (system Xc), promoting proliferation and invasion and causing neuronal death.3 Accordingly, increased glutamate levels have been implicated in numerous seizure disorders4 and contribute to epileptogenesis in glioma-implanted rodents.5, 6 Glutamate excess may cause the alteration of neuronal chloride (Cl−) homeostasis and depolarize γ-aminobutyric acid (GABA) reversal potential (EGABA), as a result of Cl− transporters dysfunction or disequilibrium.7 Indeed, a precise balance between NKCC1 and KCC2 activity is necessary for inhibitory GABAergic signaling in the adult central nervous system8 and its disequilibrium can cause elevation of intracellular [Cl−] leading to switch of GABAergic signaling from hyperpolarizing to depolarizing in epileptic tissue,9, 10 contributing to epileptogenesis.11, 12, 13
In this study, we investigated the mechanisms of glioma-induced neuronal overexcitation using co-cultures of hippocampal and glioma cells. We report that glioma cells cause the alteration of EGABA, through glutamate-receptor-dependent zinc (Zn2+) accumulation, leading to KCC2-mediated Cl− transport unbalance. Our study provides the molecular mechanism of glioma-induced elevation in intracellular Cl− and a complete model linking glutamate release by glioma cells to glioma-related epilepsy.
Results
Glioma co-culture increases neuronal [Cl-]i by a glutamatergic mechanism
To address the effect of glioma cells on neuronal Cl− equilibrium, we determined the reversal potential of the currents evoked by GABA application in mouse hippocampal cultured neurons. As shown in Figures 1a and b, co-culturing neurons with patient-derived glioma cells (MZC)14 caused a rightward shift in the current–voltage relationship of GABA-mediated responses, giving a positive shift of EGABA from −73.9±1.2 mV (control; n=124) to −52.1±1.6 mV (co-culture; n=101, P<0.001).
In control neurons, EGABA was significantly below resting membrane potential (RMP); conversely, in co-cultured neurons, despite a small depolarization of resting potential (Figure 1b), EGABA value was consistently more positive than RMP, reverting the driving force for GABA-mediated currents (Figure 1c). Similar results were observed also after a shorter (4h) co-culture duration (EGABA=−52.2±4.4 mV; n=18). EGABA shift resulted from the increase in [Cl−]i, as directly demonstrated using a genetically encoded Cl-Sensor,15, 16 which gave values similar to those calculated by Nernst equation (Figure 1d).
To investigate the possible role of glutamate released by glioma cells in EGABA depolarization, glutamate receptors (GluRs) antagonists (D-(−)-2-Amino-5-phosphonopentanoic acid (APV), 20 μM; 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide disodium salt (NBQX), 10 μM) were added to the co-culture medium. In this condition, glioma-induced EGABA depolarizing shift was prevented (Figure 2a). Similar effects were observed when co-culture experiments were performed in the sole presence of APV (EGABA=−70.6±1.96 mV; n=12, P<0.01) or NBQX (EGABA=−70.5±7.7; n=6, P<0.01), indicating that activation of both AMPA and NMDA receptors is necessary to cause EGABA shift.
In addition, when the system Xc blocker sulfasalazine (250 μM) was added to the co-culture medium, EGABA depolarization was prevented (Figure 2a), showing that this effect requires Xc-mediated glutamate release.
Moreover, acutely applied glioma-conditioned medium (GCM) activated APV/NBQX-sensitive inward currents (Figure 2b) in hippocampal neurons, confirming the presence of GluRs agonists in GCM.17
Altogether, these data show that in the co-culture conditions, glioma cells cause the depolarizing shift of Cl− equilibrium potential in neurons, through glutamate release and GluRs activation. Consistently, EGABA depolarization was observed in neurons co-cultured with different human and murine glioma cells, but not with astrocytes (Figure 2c, and Supplementary Table S1), indicating a tumor-specific effect.
Glioma-induced EGABA depolarization is due to Cl− transporters unbalance
In cultured hippocampal neurons, KCC2 and NKCC1 transporters participate in the regulation of Cl− homeostasis. Indeed, the acute application of furosemide (100 μM; 5–15 min), the blocker of both transporters, caused a minor shift in neuronal EGABA. Conversely, the specific blockers of NKCC1 (bumetanide; 10 μM; acutely applied 5–15 min) and KCC2 (R-(+)-butylindazone dihydroindenyl-oxy alkanoic acid, DIOA; 20 μM; 1 h pre-treatment plus continuous superfusion) shifted EGABA in opposite directions (Figure 3a), indicating that, in our culture conditions, both transporters actively regulate [Cl−]i.
The alteration of Cl− transporter activity is involved in glioma-induced EGABA shift in co-culture. In fact, in co-cultured neurons, furosemide, bumetanide or DIOA treatment abolished EGABA depolarization (Figure 3b). However, the acute application of bumetanide reverted the glioma-induced effect (Figures 3b and c), hyperpolarizing EGABA. Conversely, DIOA treatment significantly depolarized EGABA by itself, likely occluding co-culture depolarizing effect (Figure 3b). These data indicate that glioma-induced EGABA depolarization is due to the unbalance of cation-chloride transporters activity, likely due to KCC2 reduced function.
To disclose the effects of glioma co-culture on neuronal KCC2 protein expression, we performed immunoblot experiments, revealing that the level of transporter expression was similar in control and co-cultured neurons (Figure 3d), thus indicating that glioma-induced alteration of neuronal Cl− homeostasis relies on functional KCC2 modulation, rather than on changes in expression.
Glioma co-culture causes KCC2 impairment by increasing intracellular Zn2+ in neurons
To investigate a possible role of intracellular Zn2+ on glioma-induced EGABA shift,18 we used the membrane permeant Zn2+ chelator N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine (TPEN). TPEN application (20 μM; 5–20 min) caused the rapid recovery of neuronal EGABA from glioma-induced depolarization (Figure 4a). This result suggests that glioma-induced EGABA shift can be ascribed to KCC2 inhibition, caused by neuronal Zn2+ rise. Accordingly, when similar EGABA depolarization was obtained blocking KCC2 with the selective antagonist DIOA (20 μM; 1 h pre-treatment plus continuous superfusion), acute TPEN application had no effect (Figure 4a).
Using FluoZin-based fluorescence determinations, we also observed that basal intracellular Zn2+ was significantly higher in co-cultured neurons in respect to control (Figure 4b). Neuronal Zn2+ accumulation was prevented by APV/NBQX application in the co-culture medium (Figure 4c), indicating the requirement for GluR activation. Consistently, the application of GCM or glutamate (20 μM) onto FluoZin-loaded neurons, elicited an APV/NBQX-sensitive fluorescence increase, rapidly reverting to basal level upon TPEN application (Supplementary Figure S1 and S2).
To identify the source of Zn2+, we performed experiments in the presence of tricine, a chelator of extracellular Zn2+. Tricine treatment (1 mM, 24 h) did not abolish the effect of co-culture on EGABA (Supplementary Table S2), indicating that extracellular Zn2+ is not required for EGABA depolarization. However, co-culture induced [Zn2+]i accumulation was not observed (not shown). Noteworthy, tricine treatment caused a reduction in basal Zn2+ both in control and co-cultured neurons (n=41/59, control/co-culture; not shown). These results suggest that extracellular Zn2+ chelation modifies neuronal Zn2+ homeostasis, altering basal cytosolic Zn2+ level. To avoid possible effects on intracellular Zn2+ homeostasis, experiments with Zn2+ chelators were repeated reducing incubation time (4 h), following the observation that 4 h tricine treatment did not impair neuronal ability to release intracellular Zn2+ in response to a glutamatergic stimulus (Supplementary Figure S2). Consistently, tricine did not prevent the depolarizing effect of 4 h co-culture on EGABA (Figure 4d). Conversely, when intracellular Zn2+ was chelated (with FluoZin 5 μM, 4 h), co-culture-induced EGABA shift was abolished (Figure 4d).
All together, these data indicate that Cl− disequilibrium in co-cultured neurons is due to intracellular Zn2+-dependent KCC2 impairment.
Zn2+-mediated EGABA shift requires Src/TrkB activation
To disclose the mechanisms underlying Zn2+-mediated EGABA shift, neuronal [Zn2+]i was artificially increased through perforated (by gramicidin) patch pipette loading. We preliminarily verified the efficacy of intracellular Zn2+ loading through perforated patch by fluorescence recordings; the presence of ZnCl2 in the pipette solution caused a time- and concentration-dependent fluorescence increase in FluoZin-loaded neurons, indicating that, in our experimental conditions, Zn2+ permeates through gramicidin pores (Supplementary Table S3; Supplementary Figure S3). When 0.1 μM ZnCl2 was added to a BAPTA (5 mM) containing intracellular solution, giving a controlled free [Zn2+]i of ~10 nM (Supplementary Table S3) EGABA promptly shifted to more depolarized values (Figures 5a and b). Conversely, EGABA remained stable with control intracellular solution (calculated as~0.1 pM free [Zn2+]i, Figure 5a), or when free [Zn2+]i was below 2 nM (n=7; Supplementary Table S3). This time-dependent EGABA depolarization was not observed when cultures were treated with the KCC2 blocker DIOA (20 μM; 1 h pre-treatment plus continuous superfusion; Figure 5a and Supplementary Table S4). In these conditions, neurons displayed a depolarized EGABA, likely occluding the effects of intracellular Zn2+ loading. Consistently, acute TPEN application (15 min; Figure 5b) rapidly reverted Zn2+-induced EGABA depolarization on control neurons. These data indicate that intracellular Zn2+ level rapidly and reversibly interferes with Cl− equilibrium, through KCC2 activity modulation, highlighting intracellular Zn2+ rise as the key step in glioma-induced EGABA depolarization.
Several mechanisms have been proposed to explain KCC2 downregulation in hyperexcitability models,7, 20, 21 including the phosphorylation of KCC2 residues by a number of different kinases. To explore the mechanism of Zn2+-mediated EGABA shift, we investigated the involvement of Src/TrkB-dependent KCC2 tyrosine phosphorylation,20, 21 as intracellular Zn2+ has been reported to transactivate TrkB in a Src-dependent manner.22 When hippocampal cultures were treated with TrkB inhibitor K252A (200 nM; 1 h pre-application and perfused during the experiment), intracellular Zn2+ failed to depolarize neuronal EGABA (Figure 5c and Supplementary Table S4). Similarly, in the presence of Src kinase inhibitor PP2 (5 μM; 1 h pre-application and perfused during the experiment), EGABA shift due to intracellular Zn2+ loading was absent (Figure 5c and Supplementary Table S4). Thus, Zn2+-induced EGABA shift requires the integrity of Src/TrkB pathway.
Consistently, by western blots analysis, we demonstrated that GCM treatment (15 min) significantly increased neuronal Src phosphorylation (Figure 5d). This effect was Zn2+ dependent, as it was prevented by TPEN application (20 μM, 15 min pre-treatment and during GCM application, n=6; P=0.92 with respect to TPEN, Figure 5e). Moreover, GCM treatment significantly increased neuronal TrkB phosphorylation (Figure 5f).
Altogether, these data indicate that glioma-released factors might alter neuronal Cl− homeostasis through Zn2+-induced Src/TrkB-mediated KCC2 modulation, as illustrated in Figure 6.
Discussion
We used co-cultures of hippocampal neurons and glioma cells to unveil the mechanisms of glioma-induced hyperexcitability, reporting that glioma cells depolarize neuronal EGABA, increasing [Cl−]i and reverting the driving force for GABA-mediated currents. Our results show that EGABA depolarization relies on Zn2+-mediated KCC2 functional impairment, disclosing the underlying mechanism: glioma-released glutamate activates neuronal GluRs, causing neuronal intracellular Zn2+ rise which, through Src/TrkB activation, reduces KCC2 activity, leading to intracellular [Cl−] increase and EGABA depolarization. We conclude that glioma might reduce neuronal inhibition through Zn2+-mediated downregulation of KCC2 activity, causing hyperexcitability.
In glioma-co-cultured hippocampal neurons, the current–voltage relationship of GABA-mediated responses is shifted to more depolarized potentials, compared with control, giving a more depolarized EGABA. This indicates a higher basal neuronal [Cl−]i in co-cultures, confirmed by an independent estimation in neurons transfected with a YFP-based Cl−Sensor. Although glioma co-culture induces a small neuronal depolarization, the shift of EGABA is more relevant, resulting in the inversion of the driving force for GABA-mediated currents.
According to previous studies, Cl− homeostasis in cultured hippocampal neurons is determined by the activity of both NKCC1 and KCC2.8 Indeed, we show here that both transporters are expressed in control neurons and their activity is required to maintain Cl− equilibrium as blocking either NKCC1 or KCC2 leads to a shift in basal EGABA. Conversely, in co-cultured neurons, NKCC1 activity is apparently not balanced by KCC2-mediated Cl− extrusion and transporter disequilibrium leads to an increase in neuronal [Cl−]i. This picture is demonstrated pharmacologically by the use of selective antagonists of Cl− co-transporters: (i) furosemide, the blocker of both transporters, abolishes EGABA shift, demonstrating the involvement of Cl− transport; (ii) the specific NKCC1 antagonist bumetanide reverts co-culture-induced EGABA depolarization, demonstrating that Cl− accumulation requires the activity of NKCC1; (iii) neurons treated with the specific KCC2 blocker DIOA display depolarized EGABA, likely occluding the co-culture effect. Altogether, these data support the proposal that in neurons, a new Cl− equilibrium is established during glioma co-culture, characterized by higher [Cl−]i and caused by reduced KCC2 activity.
We provide evidence that glioma-induced KCC2 impairment, observed in co-cultured neurons, is due to intracellular Zn2+ rise.18 Indeed, intracellular Zn2+ chelation by TPEN rapidly reverts co-culture-induced EGABA shift and basal [Zn2+]i is significantly higher in neurons after glioma co-culture.
The effect of neuronal Zn2+ rise on EGABA was directly evaluated in experiments where intracellular [Zn2+] was artificially increased from pico to nanomolar, as in pathological conditions.23, 24 The resulting Zn2+-dependent EGABA shift is ascribable to KCC2 impairment, because it was absent when KCC2 was pharmacologically blocked by DIOA. Indeed, the effect of Zn2+ on EGABA is likely occluded by pharmacological KCC2 block, as DIOA treated neurons already show a depolarized EGABA, which is, consistently, not rescued by TPEN application.
Glioma-induced alteration of neuronal Cl− homeostasis likely depends on functional KCC2 block, rather than on reduction of protein expression (see Lee et al.7). This view is based on the unaltered expression of neuronal KCC2 after glioma co-culture and on the rapid rescue exerted by Zn2+ chelation, demonstrating a dynamic modulation of Cl− transport mechanisms. The functional modulation of KCC2 activity has been observed both in physiological and pathological models, such as prolonged post-synaptic spiking,25 brain-derived neurotrophic factor (BDNF) stimulation26 and oxygen glucose deprivation.18 Our data suggest that the mechanism responsible for glioma-induced KCC2 inhibition relies on Zn2+-mediated Src/TrkB activation. Indeed, Zn2+-induced EGABA shift was prevented by the application of Src or TrkB kinase inhibitors (PP2 or K252A). Consistently, GCM increased the level of TrkB and Src phosphorylation in hippocampal cultures, the latter effect being prevented by the Zn2+ chelator TPEN. These results are in line with the notion that intracellular Zn2+ may transactivate TrkB by a neurotrophin-independent and Src-dependent mechanism, as reported in models of intense neuronal activity.22
In neurons, Zn2+-induced TrkB transactivation may mimic BDNF-TrkB signaling, leading to KCC2 phosphorylation on tyrosine residues27, 28 and driving neuronal disinhibition.29 We can speculate that co-culture induced EGABA depolarization needs KCC2 phosphorylation on tyrosine residues because of Zn2+-induced TrkB transactivation.
We report that glioma-induced EGABA shift requires the release of glutamate in the extracellular space by glioma cells and the consequent activation of neuronal ionotropic GluRs. Indeed, the application of APV and NBQX during co-culture prevents EGABA depolarization.
It is known that glutamate can induce intracellular Zn2+ increase through different mechanisms, including AMPARs and Ca2+ channel-mediated influx or Ca2+-dependent intracellular release.25, 30 We observed that both APV and NBQX abolished co-culture-induced EGABA depolarization highlighting the role for both ionotropic GluRs in this effect. The simplest explanation for this evidence is that AMPAR-mediated neuronal depolarization drives NMDAR activation thus allowing Ca2+-dependent intracellular Zn2+ release.30 Our data indicate that the source of Zn2+ is intracellular, as the extracellular Zn2+ chelator tricine was ineffective, whereas FluoZin prevented co-culture-induced EGABA depolarization.
It has to be considered that tricine treatment, although did not prevent co-culture-induced EGABA depolarization, inhibited co-culture-induced basal [Zn2+]i accumulation. Thus, perturbing extracellular Zn2+ concentration may modify neuronal Zn2+ homeostasis, preventing cytosolic Zn2+ accumulation. However, tricine-treated neurons retained the ability to release intracellular Zn2+ in response to a glutamatergic stimulus, and this event is likely sufficient to trigger the intracellular signaling leading to KCC2 impairment.
It is well established that intracellular Zn2+ rise induces cell death, and Zn2+ exposure is toxic to neurons both in vitro and in vivo. It is now evident that increased cytosolic Zn2+ resulting from liberation from intracellular stores, rather than cytoplasmic influx of synaptically released Zn2+, can be highly toxic during oxidative and other types of neuronal injury,31 and Zn2+ dyshomeostasis appears to be a common feature of numerous neuropathological conditions.23, 32 We speculate that the reported mechanism, leading to reduced GABAergic transmission, could underlie the etiology of glioma-related epilepsy, pointing to Zn2+ accumulation as a possible therapeutic target to restore KCC2 function and the excitatory/inhibitory balance. In this view, it is possible to speculate that Zn2+ homeostatic drugs may be helpful in the treatment of Zn2+-related neurological disorders such as neuronal hyperexcitability or Alzheimer’s disease.33
The use of co-cultures34 allowed to disclose the molecular mechanisms involved in glutamate-mediated overexcitation induced by glioma. Our results are in line with recent works showing that Xc-mediated glutamate release is responsible for the generation of tumor-associated epileptic events in glioma-bearing mice.6, 35 Indeed, increased concentration of extracellular glutamate has been found in peritumoral tissue in both humans and mice,6, 36 supporting its role in tumor growth, survival and peritumoral seizure activity.6 Additional sources of glutamate in peritumoral tissue may be microglial Xc system or reverse activity of Na+-dependent glutamate transporters in neurons or astrocytes.37, 38 Thus, the co-culture system likely retains the feature of excessive glutamate release typical of glioma. Consistently, neuronal EGABA shift was observed in co-culturing neurons with different glioblastoma cell lines, but not with astrocytes, supporting the view of a tumor-specific effect.6
Glutamate-induced alteration of neuronal Cl− homeostasis may act concomitantly with other mechanisms, including the direct depolarizing effect of glutamate on neurons, displacing the excitation/inhibition balance toward an increased network excitability, thus promoting seizure onset.35
In conclusion, our study provides a possible explanation of the mechanisms by which glioma cells affect neuronal Cl− equilibrium, highlighting the role of Zn2+, recently emerged in a variety of excitotoxic conditions, such as epilepsy, ischemia and brain trauma.32
Materials and Methods
Animals
Procedures using laboratory animals were in accordance with the international guidelines on the ethical use of animals from the European Communities Council Directive of November 24, 1986 (86/609/EEC). All efforts were made to minimize animal suffering and to reduce the number of animals used in accordance with the European Communities Council Directive of September 20, 2010 (2010/63/UE).
Primary hippocampal neuronal cultures
Hippocampal neuronal cultures were prepared from newborn (P0-P1) C57BL/6 mice of either sex (Charles River - Research Models and Services, Lecco, Italy). In brief, after careful dissection from diencephalic structures, the meninges were removed and the hippocampi were chopped and digested in 1.25 mg/ml trypsin for 20 min at 37 °C. Cells were mechanically dissociated and plated at a density of 105 in poly-L-lysine-coated glass coverslip (12 mm diameter) in serum-free Neurobasal Medium (Gibco Life Science, Life Technologies Italia, Monza, Italy), supplemented with B27 2 mM L-glutamine and 100 μg/ml gentamicin (neuronal culture medium). Then, cells were kept at 37 °C in 5% CO2 for 10–13 days with medium replacement (1 : 1 ratio) three times per week. With this method, we obtained cultures composed by 60–70% neurons, 30–35% astrocytes and 4–5% microglia, as determined with β-tubulin III, glial fibrillary acidic protein and isolectin IB4 staining.38 The same procedure was followed to prepare rat hippocampal culture used for some immunoblot experiments.
Glial primary cultures
Primary cortical glial cells were prepared from P0-P2 mice. Cerebral cortices were chopped and digested in 30 U/ml papain for 40 min at 37 °C and gently triturated. The dissociated cells were washed, suspended in Dulbecco's Modified Eagle Medium (Gibco, Life Technologies Italia) with Glutamax with 10% fetal bovine serum (Invitrogen, Life Technologies Italia) and plated at a density of 9–10 × 105 in 175 cm2 cell culture flasks. At confluence (10–14 days in vitro, DIV), glial cells were shaken for 2 h at 37 °C to detach and remove microglial cells. These procedures gave almost pure astrocytes cell population (4–6% of microglia contamination), as verified by staining with glial fibrillary acidic protein and isolectin IB4.34
Neuronal culture transfection
Hippocampal neuronal cultures were transfected at 9–10 DIV. One day before transfection, 50% of the culture medium was replaced with fresh medium. For transfection, 100 μl of Neurobasal media were mixed with 2 μl of NeuroMag (OZ Bioscience, Marseille, France) and 1 μg of Cl-Sensor cDNA.15, 16 The mixture was incubated for 15–20 min at room temperature and thereafter distributed dropwise over the neuronal culture. Neuronal cultures were placed on a magnetic board (OZ Bioscience) and incubated for 15 min (37 °C, 5% CO2). One hour later, 50% of neuronal culture medium was substituted with fresh neuronal culture medium. Cells were used for experiments 24–76 h after transfection.
Glioma cell culture
Patient-derived glioma cells (MZC; kindly provided by Dr. Antonietta Arcella, Neuromed, Italy) within passage 40,14, 39 glioblastoma cell lines: GL15,14, 40 U87MG (American Type Culture Collection, Rochville, MD, USA) and GL26141 were grown in Dulbecco's Modified Eagle Medium with Glutamax supplemented with 10% heat-inactivated fetal bovine serum, 100 U/ml penicillin G, 2.5 μg/ml amphotericin B and 100 μg/ml streptomycin at 37 °C in a 5% CO2 humidified atmosphere. Medium was changed three times per week; cells were used between 20th and 40th passage.
Co-cultures
Glioma cells or astrocytes, prepared as above, were re-suspended in neuronal culture medium and replated by seeding 105 cells onto 0.33 cm2 transwell cell-culture inserts (pore size 0.4 μM, Corning B.V. Life Sciences, Amsterdam, The Netherlands), allowing traffic of small diffusible substances, but preventing cell-to-cell contact. Transwell inserts were transferred into 24-well cultures plates, containing 10–12 DIV primary hippocampal cultures in neuronal culture medium.
Neuronal viability after 4 and 24 h of co-culture was evaluated as reported in Supplementary Figure S4.
Patch-clamp recordings
Patch-clamp recordings were obtained using glass electrodes (3–5 MΩ) filled with the following intracellular solution (in mM): 140 KCl, 2 MgCl2, 10 HEPES, 2 MgATP, 0.5 EGTA; pH 7.3, with KOH. Perforated patch-clamp recordings with access resistances between 30 and 40 MΩ were obtained using gramicidin D.42 Gramicidin, prepared every 2 h, was added to the pipette solution to a final concentration of 50 μg/ml. During experiments, neurons were continuously superfused with normal extracellular solution containing (in mM): 140 NaCl, 2.5 KCl, 2 CaCl2, 2 MgCl2, 10 HEPES-NaOH and 10 glucose (pH 7.3), added with tetrodotoxin (0.2 μM), using a gravity-driven perfusion system, consisting of independent tubes for standard and agonist-containing solutions, connected to a fast exchanger system (RSC-100; Bio-Logic, Claix, France). All recordings were performed at 24–25 °C. For I–V experiments, neurons were voltage-clamped at −70 mV with 6-s steps to each test potential; GABA (100 μM; 500 ms; every 30 s) was applied 1 s after the voltage step onset. A linear regression was used to calculate the voltage dependence of GABA-evoked current. EGABA was taken as the intercept of this best-fit line for each cell. We minimized bicarbonate flux through the GABAA channels, using an HEPES-buffered extracellular solution (nominally CO2- and bicarbonate-free43, 44), so that EGABA was an estimation of ECl. Membrane currents, recorded with a patch-clamp amplifier (Axopatch 200B; Molecular Devices, Foster city, CA, USA), were filtered at 2 kHz, digitized (10 kHz) and acquired with Clampex 10 software (Molecular Devices). The stability of the patch was checked by repetitively monitoring the input and series resistance during the experiment, and recordings were discarded when any of these parameters changed by >10%.
Zn2+ loading through gramicidin pores
When indicated (Figure 5 and Supplementary Figure S3), intracellular [Zn2+] was artificially increased in neurons through the perforated patch, using a BAPTA-based intracellular solution (in mM: 140 KCl, 2 MgCl2, 10 HEPES, 2 MgATP, 5 BAPTA) supplemented with ZnCl2 (0.01–100 μM). The corresponding free Zn2+ concentrations were calculated using the MaxChelator software: http://www.stanford.edu/~cpatton/maxc.html, and are reported in Supplementary Table S3.
Zn+2 imaging
Fluorescence images were acquired at room temperature (24–25 °C) using a customized digital imaging microscope. Excitation of fluorophores at various wavelengths was achieved using a 1-nm-bandwidth polychromatic light selector (Till Polychrome V), equipped with a 150 W xenon lamp (Till Photonics, Hillsboro, OR, USA). Fluorescence was visualized using an upright microscope (Axioskope) equipped with a 40x water-immersion objective (Achroplan CarlZeiss, Oberkochen, Germany) and a digital 12 bit CCD camera system (SensiCam, PCO AG, Kelheim, Germany). All the peripheral hardware control, image acquisition and image processing were achieved using customized software Till Vision v. 4.0 (Till Photonics). Changes in the intracellular Zn2+ level were monitored using the high-affinity Zn2+-sensitive indicator FluoZin-3AM (Invitrogen). Neurons were loaded by incubating coverslips for 45 min at 37 °C in 1 ml of HEPES-buffered salt solution containing: 120 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.8 mM MgCl2, 20 mM HEPES-NaOH and 15 mM glucose (pH 7.3), plus 5 mg/ml of bovine serum albumin and 5 μM of FluoZin-3AM. For time-lapse recordings, FluoZin-3AM was excited at 480 nm (emission filter D535/40 nm, dichroic mirror 505DCLP). Zn2+ fluorescence changes are presented as ΔF/F0=(F−F0)/F0, or ΔFTPEN=(F0−FTPEN)/FTPEN, where F is the current fluorescence intensity, F0 is the fluorescence intensity before agonist application and FTPEN represents fluorescence intensity after 5 min of TPEN application.
Cl− imaging
For non-invasive monitoring of [Cl−]i, cells were transfected with CFP/YFP-based Cl-Sensor15 and the optic system equipped with an emission filter D535/40 nm and a dichroic mirror 505DCLP (505 nm) was used. Cells expressing Cl-Sensor were excited at 445 and 485 nm wavelengths alternatively (50 ms, 0.1 Hz). [Cl−]i changes are expressed as a ratio (R) of background-subtracted F445 and F485 (R=F445/F485). (Supplementary Figure S5) Calibration of Cl-Sensor (Supplementary Figure S6) was performed as in Markova et al.15 and Wassem et al.16 External solutions with different Cl− concentrations (in mM: 1, 3, 7, 12, 20, 35, 50, 70, 82.4, 130, 164.8) were obtained by mixing the following solutions (in mM): (i) 164.8 KCl, 10 D-glucose, 20 HEPES, pH 7.32 and (ii) 164.8 K-gluconate, 10 D-glucose, 20 HEPES, pH 7.32. To increase the permeability of the cell membrane to Cl− ions, β-escin (80 μM, Sigma, St Louis, MO, USA) was added to the extracellular solution and applied during 2–5 min. Fluorescence signals corresponding to rising Cl− concentrations were monitored from single Cl-Sensor expressing neurons, after β-escin removal.
Glioma-conditioned medium (GCM)
GCM was prepared as follows: when cultures of glioma cells became confluent (~3 × 106 in 10 cm culture dishes), the culture medium was substituted with 10 ml of filtered normal extracellular solution. The conditioned medium (GCM) was collected after incubating for 4 h, centrifuged, pH adjusted to 7.35 and then used for electrophysiological and imaging experiments.17 For immunoblot analysis of TrkB and Src activation, GCM was obtained incubating (4 h) glioma cells in Locke’s buffer (in mM: 154 NaCl, 5.6 KCl, 3.6 NaHCO3, 2.3 CaCl2, 1 MgCl2, 5.6 glucose, 5 HEPES; pH 7.4).
Cell stimulation and western blot analysis
For western blot experiments, 4 × 105 hippocampal cells were plated on poly-L-lysine coated 12-well cultures plates.45
For the analysis of TrkB and Src activation, cultured hippocampal neurons were incubated for 2 h in Locke’s buffer and stimulated for 15 min with either GCM or drugs: BDNF (100 ng/ml), platelet-derived growth factor (100 ng/ml). To assess the role of Zn2+ rise in Src phosphorylation, hippocampal cultures were treated with the Zn2+ chelator TPEN (20 μM, 15 min pre-application, and during GCM stimulation). Corresponding cell lysates were run on SDS-polyacrylamide gel and analyzed for Src or TrkB phosphorylation. Densitometric analysis was performed with QuantityOne software (Bio-Rad Laboratories S.r.l., Segrate (MI), Italy) and phosphoprotein levels were normalized for TrkB and Src expression. For KCC2 expression determination, western blot analysis was performed on rat hippocampal cell lysates in control conditions and after 24 h co-culture with equal number of glioma cells. For each condition, equal amounts of proteins were loaded on SDS-PAGE gel for immunoblot analysis with rabbit anti-KCC2. Protein levels were normalized for TuJ1 expression.
Drugs
GABA, Bicuculline methochloride, Tetrodotoxin citrate, NBQX and D-APV were purchased from Abcam Biochemicals (Cambridge, UK); Furosemide (100 mM in dimethyl sulfoxide (DMSO)), Bumetanide (50 mM in EtOH) and PP2 (10 mM in DMSO) were purchased from Tocris Biosciences (Bristol, UK); FluoZin-3AM (Invitrogen, 5 mM DMSO); K252a (Calbiochem, Merck S.p.a., Milano, Italy); DIOA (Santa Cruz Biotechnology, Inc., Heidelberg, Germany; 200 mM in EtOH); BDNF (PeproTech EC Ltd., London, UK); TPEN (10 mM in EtOH), Gramicidin (50 mg/ml in DMSO), Sulfasalazine (500 mM in DMSO), platelet-derived growth factor and all chemicals used were purchased from Sigma-Aldrich, Milan, Italy. Where not indicated, all drugs were dissolved in water. Antibodies were purchased and used as follows: rabbit anti-Phospho TrkB (phospho Y515, 1 : 500, Abcam, Cambridge, UK), rabbit anti-Phospho Src (phospho Y416, 1 : 2000, Abcam), mouse anti- Neuronal Class III β-tubulin (TuJ1, 1 : 2000, n.cat MMS-435P, Covance, San Diego, CA, USA), rabbit anti-actin (1 : 5000, Sigma-Aldrich); rabbit anti-KCC2 (1 : 1000; Millipore, Temecula, CA, USA).
Drug Application
During electrophysiological and fluorescence measurements, neurons were continuously superfused with normal extracellular solution, using a gravity-driven perfusion system, consisting of independent tubes for standard and agonist-containing (GABA, GCM) solutions, connected to a fast exchanger system (RSC-100; Bio-Logic) positioned 50–100 μm from the cell. Antagonists were usually acutely applied through a parallel tubes of the same perfusion system. DIOA, K252A and PP2 were pre-incubated for 1 h (37 °C) and then continuously applied during the experiments. Sulfasalazine, APV/NBQX, BAPTA-AM and tetrodotoxin citrate were applied during co-culture in the co-culture medium and not superfused during recordings (24 h). The values of EGABA and RMP of control neurons, following different drug treatments are reported in Supplementary Table S2 and Supplementary Table S4.
Data analysis
Data, analyzed offline, are presented as mean±S.E.M.; we used the QuantityOne (Bio-Rad Laboratories S.r.l.) program for the densitometric analysis of all immunoblots. Origin 7 (Origin software; Microcal Software, Northampton, MA, USA) and Sigmaplot 11 (Systat Software Inc, London, UK) software were used for statistical analysis. Paired and unpaired t-test and one-way ANOVA were used for parametrical data, as indicated; Tukey test was used as post hoc test; Mann and Withney test for non parametrical data. We constructed I–V plots, cumulative distribution plots and fitted data points by linear or non-linear regression analysis using Origin software. Statistical significance for cumulative distributions was assessed with Kolmogorov-Smirnov test.
Abbreviations
- EGABA:
-
Reversal potential of GABA-evoked currents
- system Xc:
-
glutamate-cystine transporter
- APV:
-
D-2-amino-5-phosphonopentanoic
- [Cl-]I:
-
chloride concentration
- DMSO:
-
dimethyl sulfoxide
- GABA:
-
γ-aminobutyric acid
- GCM:
-
glioma-conditioned medium
- Glu:
-
glutamate
- NBQX:
-
2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]quinoxaline-2,3-dione
- RMP:
-
resting membrane potential
- DIOA:
-
R-(+)-butylindazone dihydroindenyl-oxy alkanoic acid
- TPEN:
-
N,N,N′,N′-tetrakis(2-pyridylmethyl)ethylenediamine
References
Moots PL, Maciunas RJ, Eisert DR, Parker RA, Laporte K, Abou-Khalil B . The course of seizure disorders in patients with malignant gliomas. Arch Neurol 1995; 52: 717–724.
Khan T, Akhtar W, Wotton CJ, Hart Y, Turner MR, Goldacre MJ . Epilepsy and the subsequent risk of cerebral tumour: record linkage retrospective cohort study. J Neurol Neurosurg Psychiatry 2011; 82: 1041–1045.
Sontheimer H . Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci 2003; 26: 543–549.
Cavus I, Kasoff WS, Cassaday MP, Jacob R, Gueorguieva R, Sherwin RS et al. Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol 2005; 57: 226–235.
Köhling R, Senner V, Paulus W, Speckmann EJ . Epileptiform activity preferentially arises outside tumor invasion zone in glioma xenotransplants. Neurobiol Dis 2006; 22: 64–75.
Buckingham SC, Campbell SL, Haas BR, Montana V, Robel S, Ogunrinu T et al. Glutamate release by primary brain tumors induces epileptic activity. Nat Med 2011; 17: 1269–1274.
Lee HH, Deeb TZ, Walker JA, Davies PA, Moss SJ . NMDA receptor activity downregulates KCC2 resulting in depolarizing GABAA receptor-mediated currents. Nat Neurosci 2011; 14: 736–743.
Blaesse P, Airaksinen MS, Rivera C, Kaila K . Cation-chloride cotransporters and neuronal function. Neuron 2009; 61: 820–838.
Cohen I, Navarro V, Clemenceau S, Baulac M, Miles R . On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002; 298: 1418–1421.
Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci 2007; 27: 9866–9873.
Palma E, Amici M, Sobrero F, Spinelli G, Di Angelantonio S, Ragozzino D et al. Anomalous levels of Cl- transporters in the hippocampal subiculum from temporal lobe epilepsy patients.make GABA excitatory. Proc Natl Acad Sci USA 2006; 103: 8465–8468.
Barmashenko G, Hefft S, Aertsen A, Kirschstein T, Köhling R . Positive shifts of the GABAA receptor reversal potential due to altered chloride homeostasis is widespread after status epilepticus. Epilepsia 2011; 52: 1570–1578.
Conti L, Palma E, Roseti C, Lauro C, Cipriani R, de Groot M et al. Anomalous levels of Cl- transporters cause a decrease of GABAergic inhibition in human peritumoral epileptic cortex. Epilepsia 2011; 52: 1635–1644.
Sciaccaluga M, Fioretti B, Catacuzzeno L, Pagani F, Bertollini C, Rosito M et al. CXCL12-induced glioblastoma cell migration requie intermediate conductance Ca2+-activated K+ channel activity. Am J Physiol Cell Physiol 2010; 299: 175–184.
Markova O, Mukhtarov M, Real E, Jacob Y, Bregestovski P . Genetically encoded chloride indicator with improved sensitivity. J Neurosci Methods 2008; 170: 67–76.
Waseem T, Mukhtarov M, Buldakova S, Medina I, Bregestovski P . Genetically encoded Cl-Sensor as a tool for monitoring of Cl-dependent processes in small neuronal compartments. J Neurosci Methods 2010; 193: 14–23.
Bertollini C, Murana E, Mosca L, D’Erme M, Scala F, Francioso A et al. Transient increase in neuronal chloride concentration by neuroactive amino acids released from glioma cells. Front Mol Neurosci 2012; 5: 100.
Hershfinkel M, Kandler K, Knoch ME, Dagan-Rabin M, Aras MA, Abramovitch-Dahan C et al. Intracellular zinc inhibits KCC2 transporter activity. Nat Neurosci 2009; 12: 725–727.
Chorin E, Vinograd O, Fleidervish I, Gilad D, Herrmann S, Sekler I et al. Upregulation of KCC2 activity by zinc-mediated neurotransmission via the mZnR/GPR39 receptor. J Neurosci 2011; 31: 12916–12926.
Rivera C, Voipio J, Thomas-Crusells J, Li H, Emri Z, Sipilä S et al. Mechanism of activity-dependent downregulation of the neuron-specific K-Cl cotransporter KCC2. J Neurosci 2004; 24: 4683–4691.
Wake H, Watanabe M, Moorhouse AJ, Kanematsu T, Horibe S, Matsukawa N et al. Early changes in KCC2 phosphorylation in response to neuronal stress result in functional downregulation. J Neurosci 2007; 27: 1642–1650.
Huang YZ, Pan E, Xiong ZQ, McNamara JO . Zinc-mediated transactivation of TrkB potentiates the hippocampal mossy fiber-CA3 pyramid synapse. Neuron 2008; 57: 546–558.
Sensi SL, Paoletti P, Bush AI, Sekler I . Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 2009; 10: 780–791.
Frederickson CJ, Koh JY, Bush AI . The neurobiology of zinc in health and disease. Nat Rev Neurosci 2005; 6: 449–462.
Sensi SL, Ton-That D, Weiss JH . Mitochondrial sequestration and Ca(2+)-dependent release of cytosolic Zn(2+) loads in cortical neurons. Neurobiol Dis 2002; 10: 100–108.
Wardle RA, Poo MM . Brain-derived neurotrophic factor modulation of GABAergic synapses by postsynaptic regulation of chloride transport. J Neurosci 2003; 23: 8722–8732.
Medina I, Friedel P, Rivera C, Kahle KT, Kourdougli N, Uvarov P et al. Current view on the functional regulation of the neuronal K(+)-Cl(−) cotransporter KCC2. Front Cell Neurosci 2014; 8: 27.
Kahle KT, Deeb TZ, Puskarjov M, Silayeva L, Liang B, Kaila K et al. Modulation of neuronal activity by phosphorylation of the K-Cl cotransporter KCC2. Trends Neurosci 2013; 36: 726–737.
Ferrini F, De Koninck Y . Microglia control neuronal network excitability via BDNF signalling. Neural Plast 2013; 2013: 429815.
Dineley KE, Devinney MJ 2nd, Zeak JA, Rintoul GL, Reynolds IJ . Glutamate mobilizes [Zn2+] through Ca2+ -dependent reactive oxygen species accumulation. J Neurochem 2008; 106: 2184–2193.
McCord MC, Aizenman E . The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease. Front Aging Neurosci 2014; 6: 77.
Sensi SL, Paoletti P, Koh JY, Aizenman E, Bush AI, Hershfinkel M . The neurophysiology and pathology of brain zinc. J Neurosci 2011; 31: 16076–16085.
Zatta P, Drago D, Bolognin S, Sensi SL . Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 2009; 30: 346–355.
Rosito M, Deflorio C, Limatola C, Trettel F . CXCL16 orchestrates adenosine A3 receptor and MCP-1/CCL2 activity to protect neurons from excitotoxic cell death in the CNS. J Neurosci 2012; 32: 3154–3163.
Campbell SL, Buckingham SC, Sontheimer H . Human glioma cells induce hyperexcitability in cortical networks. Epilepsia 2012; 53: 1360–1370.
Marcus HJ, Carpenter KL, Price SJ, Hutchinson PJ . In vivo assessment of high-grade glioma biochemistry using microdialysis: a study of energy-related molecules, growth factors and cytokines. J Neurooncol 2010; 1: 11–23.
Kettenmann H, Hanisch UK, Noda M, Verkhratsky A . Physiology of microglia. Physiol Rev 2011; 91: 461–553.
Buckingham SC, Robel S . Glutamate and tumor-associated epilepsy: glial cell dysfunction in the peritumoral environment. Neurochem Int 2013; 63: 696–701.
Lauro C, Cipriani R, Catalano M, Trettel F, Chece G, Brusadin V et al. Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death. Neuropsychopharmacology 2010; 35: 1550–1559.
D'Onofrio M, Arcella A, Bruno V, Ngomba RT, Battaglia G, Lombari V et al. Pharmacological blockade of mGlu2/3 metabotropic glutamate receptors reduces cell proliferation in cultured human glioma cells. J Neurochem 2003; 84: 1288–1295.
D'Alessandro G, Catalano M, Sciaccaluga M, Chece G, Cipriani R, Rosito M et al. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death Dis 2013; 4: e773.
Cantini G, Pisati F, Pessina S, Finocchiaro G, Pellegatta S . Immunotherapy against the radial glia marker GLAST effectively triggers specific antitumor effectors without autoimmunity. Oncoimmunology 2012; 1: 884–893.
Akaike N . Gramicidin perforated patch recording and intracellular chloride activity in excitable cells. Prog Biophys Mol Biol 1996; 65: 251–264.
Autere AM, Lamsa K, Kaila K, Taira T . Synaptic activation of GABAA receptors induces neuronal uptake of Ca2+ in adult rat hippocampal slices. J Neurophysiol 1999; 81: 811–816.
Lauro C, Di Angelantonio S, Cipriani R, Sobrero F, Antonilli L, Brusadin V et al. Activity of adenosine receptors type 1 Is required for CX3CL1-mediated neuroprotection and neuromodulation in hippocampal neurons. J Immunol 2008; 180: 7590–7596.
Acknowledgements
This study is dedicated to the memory of Professor Fabrizio Eusebi, who initiated and inspired this direction of research. The work was supported by grants from PRIN 2009 (to DR, CL and SDA) and AIRC to CL. EM was supported by PhD programme in Neurophysiology, Sapienza University, Rome. Authors wish to thank Dr. Stefano Sensi for critical reading of the manuscript and precious suggestions.
Author Contributions
SDA designed, carried out and analyzed all perforated patch clamp experiments; SC, FS and MGM performed whole-cell recordings; CL and CL designed, carried out and analyzed western blot experiments. Imaging experiments were designed, carried out and analyzed by EM, CB, PB and DR; DR and SDA conceived the project and wrote the manuscript with the help of PB and original input from Fabrizio Eusebi.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interests.
Additional information
Edited by A Verkhratsky
Supplementary Information accompanies this paper on Cell Death and Disease website
Supplementary information
Rights and permissions
Cell Death and Disease is an open-access journal published by Nature Publishing Group. This work is licensed under a Creative Commons Attribution 4.0 International Licence. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons licence, users will need to obtain permission from the licence holder to reproduce the material. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0
About this article
Cite this article
Di Angelantonio, S., Murana, E., Cocco, S. et al. A role for intracellular zinc in glioma alteration of neuronal chloride equilibrium. Cell Death Dis 5, e1501 (2014). https://doi.org/10.1038/cddis.2014.437
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cddis.2014.437
This article is cited by
-
Neuronal K+-Cl- cotransporter KCC2 as a promising drug target for epilepsy treatment
Acta Pharmacologica Sinica (2024)
-
Novel fragile X syndrome 2D and 3D brain models based on human isogenic FMRP-KO iPSCs
Cell Death & Disease (2021)
-
Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma
Scientific Reports (2018)
-
Glia as drivers of abnormal neuronal activity
Nature Neuroscience (2016)